Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Molecular Basis for the Potentiation and Subtype Specificity of Voltage Gated Potassium Channels
FY 2015-16
Summary
Epilepsy is the fourth most common neurological disorder and associated with multiple co-morbidities. Most current antiepileptic drugs target sodium channels or GABA signalling, but have significant drawbacks. Many epileptic patients experience side effects, and roughly 30% of patients are 'intractable' or unresponsive to current antiepileptic medications. In addition to incurring economic stress from continuous treatment attempts, intractable epileptics show lower self-esteem, more anxiety and depression, have greater social isolation, and are often stigmatized. For them, novel drug targets represent a major hope of managing their seizures. Retigabine is the first class of antiepileptic drug that acts by potentiating voltage gated potassium channels (KCNQ2-5) to dampen neuronal excitation. KCNQ channels assemble as heterotetramers and channel subtypes have diverse tissue distribution which contributes to peripheral retigabine side effects, such as urinary retention. As a result, retigabine analogues such as ICA069673 are currently being investigated for the development of more effective and selective KCNQ channel activators. My project will investigate how these novel KCNQ channel activators generate subtype specificity. Collectively, these experiments will deepen our understanding of the molecular basis of KCNQ channel opener effects, and how these drugs may be improved to better combat epilepsy.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
349939
Name
Wang Caroline
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Molecular Basis for the Potentiation and Subtype Specificity of Voltage Gated Potassium Channels
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Epilepsy; Inteins; Kcnq2/3; Retigabine And Retigabine Analogues; Voltage Dependence
Abstract
Epilepsy is the fourth most common neurological disorder and associated with multiple co-morbidities. Most current antiepileptic drugs target sodium channels or GABA signalling, but have significant drawbacks. Many epileptic patients experience side effects, and roughly 30% of patients are 'intractable' or unresponsive to current antiepileptic medications. In addition to incurring economic stress from continuous treatment attempts, intractable epileptics show lower self-esteem, more anxiety and depression, have greater social isolation, and are often stigmatized. For them, novel drug targets represent a major hope of managing their seizures. Retigabine is the first class of antiepileptic drug that acts by potentiating voltage gated potassium channels (KCNQ2-5) to dampen neuronal excitation. KCNQ channels assemble as heterotetramers and channel subtypes have diverse tissue distribution which contributes to peripheral retigabine side effects, such as urinary retention. As a result, retigabine analogues such as ICA069673 are currently being investigated for the development of more effective and selective KCNQ channel activators. My project will investigate how these novel KCNQ channel activators generate subtype specificity. Collectively, these experiments will deepen our understanding of the molecular basis of KCNQ channel opener effects, and how these drugs may be improved to better combat epilepsy.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wang, Caroline
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~